Prevalence of renal complications of levetiracetam in neonates with seizures in Qom from 2015 to 2020
Journal of Pediatric Nephrology,
Vol. 9 No. 4 (2021),
10 Aban 2021
Introduction: Spasms or seizures during the first month of life are the most common clinical manifestations of central nervous system failure in infants and occur due to overactivity of a group of nerve cells in the brain and excessive electrical stimulation of neurons. The purpose of the present study was to evaluate the prevalence of renal complications of Levetiracetam in neonates with seizures.
Methods: This descriptive-analytical and retrospective study was performed on creatinine level, blood urea and duration of levetiracetam use for all neonates studied and only renal ultrasound was performed for cases where their creatinine was elevated. Finally, the obtained information was used for statistical analysis.
Results: According to the results, there was no statistically significant differences in neonatal subgroups, especially in infants on levetiracetam, except transient increased creatinine and urea. During 6 months follow-up, only three cases with increased creatinine above 1.4 was observed. This 3 cases had normal genitourinary ultrasound. Also, in neonates diagnosed with choroid cyst on ultrasound, in one case the creatinine level was more than 1.4 and in the other cases the serum creatinine level was less than 1.4.
Conclusion: According to the results of the present study, no serious renal complication was observed with Levetiracetam and its use can be recommended for patients.
- Levetiracetam; Renal complications; infants
How to Cite
2. Mollamohammadi M, Amirhoseini ZS, Saadati A, Pirzadeh Z, Amouzadeh MH. Oral levetiracetam as add-on therapy in refractory neonatal seizures. Iranian journal of child neurology. 2018;12(4):103.
3. Dimassi S, Labalme A, Ville D, Calender A, Mignot C, Boutry‐Kryza N, et al. Whole‐exome sequencing improves the diagnosis yield in sporadic infantile spasm syndrome. Clinical genetics. 2016;89(2):198-204.
4. Glass HC. Neonatal seizures: advances in mechanisms and management. Clinics in perinatology. 2014;41(1):177-90.
5. Marcdante K, Kliegman R. Seizures. Nelson Essentials of Pediatrics 8th ed Philadelphia, PA: Elsevier. 2019.
6. Le Coz J, Chéron G, Nabbout R, Patteau G, Heilbronner C, Hubert P, et al. Diagnostic evaluation and management of seizures and status epilepticus in children with known epilepsy or new-onset seizures: A retrospective and comparative analysis. Archives de Pédiatrie. 2020;27(2):66-71.
7. Scher M. Neonatal seizures. Epilepsy Syndromes E-Book. 2017:49.
8. Samanta D. Recent Advances in the Diagnosis and Treatment of Neonatal Seizures. Neuropediatrics. 2020.
9. Shellhaas RA, editor Continuous long-term electroencephalography: the gold standard for neonatal seizure diagnosis. Seminars in Fetal and Neonatal Medicine; 2015: Elsevier.
10. Alix V, James M, Jackson AH, Visintainer PF, Singh R. Efficacy of fosphenytoin as first-line antiseizure medication for neonatal seizures compared to phenobarbital. Journal of Child Neurology. 2021;36(1):30-7.
11. Polavarapu A, Hasbani D, editors. Neurological complications of nutritional disease. Seminars in pediatric neurology; 2017: Elsevier.
12. Pisani F, Spagnoli C, editors. Acute symptomatic neonatal seizures in preterm neonates: etiologies and treatments. Seminars in Fetal and Neonatal Medicine; 2018: Elsevier.
13. Meyer JM. Pharmacotherapy of psychosis and mania. Goodman and Gilman’s the pharmacological basis of therapeutics. 2011:417-56.
14. Nimaga K, Desplats D, Doumbo O, Farnarier G. Treatment with phenobarbital and monitoring of epileptic patients in rural Mali. Bulletin of the World Health Organization. 2002;80:532-7.
15. Lerman-Sagie T, Lerman P. Phenobarbital still has a role in epilepsy treatment. Journal of child neurology. 1999;14(12):820-1.
16. Wagner CB, Kreimer AM, Carrillo NP, Autry E, Schadler A, Cook AM, et al. Levetiracetam Compared to Phenobarbital as a First Line Therapy for Neonatal Seizures: An Unexpected Influence of Benzodiazepines on Seizure Response. The Journal of Pediatric Pharmacology and Therapeutics. 2021;26(2):144-50.
17. Mruk AL, Garlitz KL, Leung NR. Levetiracetam in neonatal seizures: a review. The Journal of Pediatric Pharmacology and Therapeutics. 2015;20(2):76-89.
18. Rakshasbhuvankar A, Rao S, Kohan R, Simmer K, Nagarajan L. Intravenous levetiracetam for treatment of neonatal seizures. Journal of Clinical Neuroscience. 2013;20(8):1165-7.
19. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. european journal of paediatric neurology. 2011;15(1):1-7.
20. Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatric neurology. 2011;44(4):265-9.
21. Spengler DC, Montouris GD, Hohler AD. Levetiracetam as a possible contributor to acute kidney injury. Clinical therapeutics. 2014;36(8):1303-6.
22. Yau K, Burneo JG, Jandoc R, McArthur E, Muanda FT, Parikh CR, et al. Population-based study of risk of AKI with levetiracetam. Clinical Journal of the American Society of Nephrology. 2019;14(1):17-26.
23. Erdinc B, Ghanta S, Andreev A, Elkholy KO, Sahni S. Acute Kidney Injury Caused by Levetiracetam in a Patient With Status Epilepticus. Cureus. 2020;12(6).
24. Shiue HJ, Taylor M, Sands KA. Comparison of levetiracetam dosing regimens in end-stage renal disease patients undergoing intermittent hemodialysis. Annals of Pharmacotherapy. 2017;51(10):862-5.
25. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology & Therapeutics. 2000;85(2):77-85.
26. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER™ 1KEEPER is a trademark of UCB S.A.1 trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Research. 2003;54(2):153-61.
27. Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, et al. Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Research. 2005;63(1):1-9.
28. Tanaka S, Tanaka T. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy. Epileptic disorders. 2013;15(2):132-41.
29. Noyer M, Gillard M, Matagne A, Hénichart J-P, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European journal of pharmacology. 1995;286(2):137-46.
30. Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, et al. Multicenter double‐blind, randomized, placebo‐controlled trial of levetiracetam as add‐on therapy in Chinese patients with refractory partial‐onset seizures. Epilepsia. 2009;50(3):398-405.
31. Cataldi M, Lariccia V, Secondo A, Di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1, 4, 5-trisphosphate-dependent [Ca2+] I increase induced by ATP and bradykinin in PC12 cells. Journal of Pharmacology and Experimental Therapeutics. 2005;313(2):720-30.
- Abstract Viewed: 174 times
- PDF Downloaded: 130 times